ArticleInternational journal of cardiology. Cardiovascular risk and prevention2025
Burden of ischemic heart disease in China from 1990 to 2021: Data from the global disease burden database 2021.
Article in International journal of cardiology. Cardiovascular risk and prevention, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aims to analyze the disease burden of ischemic heart disease (IHD) in China from 1990 to 2021 utilizing data from Global Burden of Disease (GBD) 2021 database. Methods: Data from the GBD 2021 database were used to evaluate the prevalence, incidence, mortality, disability-adjusted life years (DALYs), years lived with disability (YLDs), and years of life lost (YLLs) attributable to IHD in China from 1990 to 2021. Age-standardized rates and Joinpoint analysis were employed to assess temporal trends, with comparisons across gender and age groups. Results: In 2021, the incidence rate was 365.67 per 100,000 population (95 % CI: 293.32-440.07), and the mortality rate was 110.91 per 100,000 population (95 % CI: 92.42-128.56). Males exhibited a significantly higher disease burden compared to females. Among the population, incidence rates increased markedly after age 60, peaking at ages 70-74, while mortality rates rose sharply after age 75. From 1990 to 2021, the incidence, prevalence, mortality, and DALY rates showed an upward trend. However, after age standardization, the trends for incidence and prevalence flattened, while mortality and DALY rates showed a downward trend. Joinpoint analysis indicated a downward trend in age-standardized incidence, prevalence, mortality, and DALY rates. Conclusion: The overall burden of IHD in China remains high, but age-standardized data reflects the effectiveness of disease prevention and control. In the future, greater emphasis should be placed on high-risk populations, particularly aging population and postmenopausal women, to further alleviate the social burden of IHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.